AM-Pharma Announces the Appointment of Rita Jain M.D. to its Supervisory Board
Utrecht, The Netherlands, 1 July 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Rita Jain, M.D., to the Company’s Supervisory Board. With over 20 years of experience in pharmaceutical development, Dr. Jain most recently was Senior Vice President and Chief Medical Officer at […]
AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team
Utrecht, The Netherlands, June 29, 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Wolfgang Meder, Ph.D., as Vice President, Regulatory Affairs and Quality Management, and Laetitia Szaller as General Counsel & Vice President, Business Development. Dr. Meder, who brings nearly 20 years of […]
AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI
€23m (US$25.5m) equity provided mainly by US-based Cowen Healthcare Investments €24m (US$26.5m) finance facility provided by the European Investment Bank (EIB) Increased funding allows for finalization of all Marketing Authorization Application preparation activities Utrecht, The Netherlands, 31 March 2020 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company leading in the development of […]
AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury
Juliane Bernholz has joined as Chief Operating Officer Kristie Bass has joined as VP Clinical Operations Bunnik, The Netherlands, 1 October 2019 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP) today […]
AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury
Financing co-led by new investors LSP and Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to be used for the 1,400-patient international pivotal Phase III trial of recombinant human Alkaline Phosphatase (recAP) in patients with sepsis-associated acute kidney injury (SA-AKI) AKI […]
JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
JAMA paper to be presented at ESICM conference in Paris New data on mode of action to be presented at ASN conference in San Diego Bunnik, The Netherlands, 24th October 2018. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, today publishes data in the prestigious Journal of the […]
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
Study shows use of recAP results in greater than 40% relative reduction in mortality Bunnik, The Netherlands, 9th March 2018. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, today announced positive results from its adaptive Phase II study in 301 sepsis patients with Acute Kidney Injury […]
